下午茶是英国文化的重要象征，也是激发对话与联结的独特时刻。药明康德始终相信，当我们以改善全球患者健康为共同目标，当思想交汇，进步便由此开始。在柔和的光线、放慢的时间节奏与轻松的对话氛围中，思维得以从紧绷转向自由流动，而灵感往往正是在这种微妙的节奏切换中迸发。

当天，近200位全球产业领袖齐聚一堂，在开放的交流空间里深入探讨：欧洲创新如何走向世界，如何让更多突破性疗法惠及全球患者。

欧洲创新正在重新被看见

从青霉素的诞生到霍乱病因的揭示，伦敦长期引领生命科学前沿。如今，它与牛津、剑桥共同构成“黄金三角”，已成为欧洲最具活力的生命科学集群之一。

全球前20大医药企业中，有19家在伦敦设立基地；众多顶尖大学、研究机构和超过2700家公司在此集聚。今年以来，该地区生命科学领域吸引了16亿英镑风险投资，几乎是2024年的两倍。

这也是欧洲创新复兴的缩影。

在下午茶圆桌讨论中，三位欧美顶尖生命科学投资人不约而同指出：“欧洲从不缺伟大的科学，缺的只是‘放大器’。”

“欧洲是值得期待的新药发现引擎。”Medicxi联合创始人兼合伙人Francesco De Rubertis博士表示，每年获得FDA批准的药物中，有10%–20%是在欧洲发现的。

Sofinnova Partners董事长Antoine Papiernik先生也强调，过去几十年里欧洲生物医药产业持续提升，已成为“能够影响全球的重要创新支柱”。

然而，相比科学实力，早期风险投资仍显不足，这也成为今年Jefferies大会的重要讨论议题。

Canaan Partners普通合伙人Nina Kjellson女士认为，这是挑战，也是欧洲的重大机遇。“我们最近投资的十个项目中，有四个来自欧洲。”

此前，Canaan早期投资的Halda Therapeutics被强生以超30亿美元收购，而她在欧洲布局的项目正凭借扎实的早期数据迈入临床，有望复制这一成功。

类似的，Sofinnova Partners近期完成6.5亿欧元募资，Medicxi则新募集5亿欧元基金。两家机构都希望继续扎根欧洲科学，寻找下一家具有颠覆潜力的初创公司。

合作，是穿越周期的确定性

正如Papiernik先生在讨论中指出的那样：“无论外部环境如何变化，稳定可靠的合作关系永远是成功的关键。我们投资的公司里，很多都和药明康德平台有着合作，他们是值得信赖的伙伴。”

从挑战难成药靶点的新分子，到多肽、寡核苷酸等新兴领域，创新边界不断被突破。

在产业面临日益复杂性的当下，药明康德将继续凭借CRDMO平台的全球能力与布局，为全球合作伙伴提供更加灵活、韧性的选择。

在药明康德数千家合作伙伴中，相当一部分来自欧洲。为了满足他们的创新需求，药明康德日前宣布在慕尼黑进一步设立欧洲区域总部，点燃欧洲的创新加速度。

欧洲之外，药明康德同样在全球各地建能力，扩规模，以独特的CRDMO平台提供赋能：

在北美，位于美国特拉华州的米德尔顿基地预计将于2026年底前投入运营，为全球客户提供从临床前到商业化阶段的制剂开发与生产服务；

在亚太，新加坡的原料药生产基地计划于2027年起陆续投入运营，为小分子、寡核苷酸、多肽及复杂偶联药物提供服务；

在中东，药明康德也与沙特新未来城（NEOM）和沙特卫生部分别签署战略合作备忘录，探索在沙特开展新药研发与生产服务的本地化进程。

一路走来，药明康德联席首席执行官杨青博士感谢全球客户25年来的信任与同行。

“我们致力于成为加速创新的粘合剂，在这个充满不确定性的时代，为全球合作伙伴带来‘稳定性’。”

让创新在“同一张桌子上”共振

在来自欧洲、北美及全球产业领袖的深度交流中，一个清晰的信号跃然呈现：

欧洲创新正重回全球聚光灯，而真正推动它前行的，是产业间的互信与开放合作。

在“下午茶”这一文化符号中，生物医药产业的共同价值再次被点亮——连接、信任、合作，以及对创新不灭的信念。

当生态圈的伙伴们围坐在同一张“桌子”旁，让思想自由流动，创新便得以发生，也将更快抵达患者。

By the Thames, We Ignite Europe’s Innovation Momentum

For 25 years, WuXi AppTec has embraced openness, collaboration, and a spirit of transformation, empowering the global biopharmaceutical industry to accelerate drug discovery and development, and fostering deeper connectivity across the world’s innovation ecosystems.

Last week, during the Jefferies Global Healthcare Conference — often called the “JPM of Europe” — WuXi AppTec hosted a WuXi Innovation Day at the Savoy Hotel. As the first modern hotel in the UK, the Savoy pioneered the use of electricity, hot running water, and elevators more than a century ago. It quickly became a symbol of progress and a venue for important dialogues that propelled global progress. Today, this iconic landmark once again brings innovators together for meaningful exchange.

Afternoon tea is a hallmark of British culture — a moment for connection and conversation. At WuXi AppTec, we believe that when we share a common goal of improving patient health worldwide, and when ideas converge, progress naturally follows. Under soft daylight and in a relaxed, unhurried atmosphere, minds shift from tension to flow, and inspiration often emerges precisely in these subtle transitions of rhythm.

Nearly 200 industry leaders from around the world joined us, engaging in open conversations on how European innovation can better reach global patients and create broader impact.

European Innovation in the Spotlight

From the discovery of penicillin to the elucidation of cholera’s cause, London has long stood at the forefront of life sciences. Today, together with Oxford and Cambridge, it forms the renowned “Golden Triangle,” one of Europe’s most dynamic scientific clusters.

Nineteen of the world’s top 20 pharmaceutical companies have a presence in London. Leading universities, research institutions, hospitals, and more than 2,700 life sciences companies form a thriving ecosystem. Since the beginning of this year, the region has attracted £1.6 billion in venture capital — nearly double the amount in 2024.

This reflects a broader renaissance of European innovation.

During the panel discussion at WuXi Innovation Day, three leading European and U.S. life sciences investors shared a common perspective: “Europe never lacked great science — it just lacked amplifiers.”

“Europe is a promising engine for new drug discovery,” said Dr. Francesco De Rubertis, Co-Founder and Partner at Medicxi. He noted that 10%–20% of all FDA-approved drugs each year have European origins.

Sofinnova Partners Chairman and Managing Partner Antoine Papiernik echoed this view, emphasizing that Europe’s biopharmaceutical sector has significantly strengthened over the past decades and has become “a major pillar of innovation capable of influencing the world.”

However, compared with its scientific prowess, Europe’s early-stage venture funding remains insufficient — a key topic at this year’s Jefferies conference.

This gap, argued Canaan Partners General Partner Nina Kjellson, represents a major opportunity: “Of the last ten assets we invested in, four came from Europe.”

One of Canaan’s early investments, Halda Therapeutics, was recently acquired by Johnson & Johnson in a deal valued at over $3 billion. Several of her European portfolio companies, she noted, are now advancing into clinical development and may follow a similar trajectory.

Likewise, Sofinnova Partners recently closed an €650 million fund, while Medicxi raised €500 million for its latest fund — both aiming to back the next generation of disruptive European startups.

Collaboration: The Certainty That Carries Us Through Cycles

“Remembering who your trusted partners are and continuing to work with them. Many of our companies collaborate with WuXi AppTec. What’s essential is staying with what works.” Antoine said during the panel discussion.

From emerging modalities targeting previously undruggable biology to peptides, oligonucleotides, and beyond, innovation boundaries are being continually redefined.

As the industry faces growing complexity, WuXi AppTec will continue expanding its global CRDMO capabilities to provide partners with more flexible, resilient, and scalable support.

Among WuXi AppTec’s thousands of partners, a significant number are based in Europe. To better meet their innovation needs, WuXi AppTec recently announced the establishment of its European regional headquarters in Munich—further igniting the continent’s innovation momentum.

Beyond expanding in Europe, the company is continuously building capability and expand capacity worldwide. 

In North America, the Middleton, U.S. site is expected to be operational by the end of 2026, providing formulation development and manufacturing services from preclinical to commercial stages. 

In Asia-Pacific, the Singapore API facility will begin phased operations in 2027, supporting small molecules, oligonucleotides, peptides, and complex conjugates. 

In the Middle East, WuXi AppTec is partnering with NEOM and the Ministry of Health of the Kingdom of Saudi Arabia to explore the localization of pharmaceutical research, development and manufacturing in Saudi Arabia.

Dr. Steve Yang, Co-CEO of WuXi AppTec, expressed deep gratitude for the trust our global partners have placed in us over the past 25 years.

“In an era of uncertainty, we strive to be the adhesive that accelerates innovation — and the stability our global partners can rely on.”

Innovation Resonates “At the Same Table”

Through conversations among leaders from Europe, North America, and around the world, one message emerged clearly:

Europe’s innovation is returning to the global spotlight, and what propels it forward is trust and open collaboration across the industry.

Within this cultural moment, symbolized by a shared table and shared dialogue, the core values of biopharmaceutical innovation once again came to light: connection, trust, cooperation, and an unwavering belief in discovery.

When partners across the ecosystem sit together and share ideas freely, innovation begins to resonate. And breakthroughs reach patients faster.